Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Plitidepsin (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ADMYRE
  • Sponsors PharmaMar
  • Most Recent Events

    • 04 Oct 2017 According to a PharmaMar media release, the company has submitted a Marketing Authorisation Application to the Swiss Agency for Therapeutic Products (Swissmedic) for Aplidin for the treatment of patients with multiple myeloma.
    • 21 Sep 2017 Planned End Date changed from 1 may 2017 to 1 Nov 2017.
    • 21 Sep 2017 Planned primary completion date changed from 1 may 2017 to 1 nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top